AGC Biologics Completes pDNA and mRNA Line Expansion in Heidelberg

AGC Biologics, a global Biopharmaceutical CDMO, completed the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at its Heidelberg, Germany site.
 
With this expansion and added production line, AGC Biologics can now offer more plasmid material in high-quality and GMP grades and expand the services it offers for mRNA supply. The addition to the Heidelberg facility uses state-of-the-art single-use equipment, creating the flexibility to produce different projects simultaneously with shorter timelines and faster project turnover, according to the company.
 
The new line includes optimized personnel and material flow, new clean rooms for fermentation, chromatography, laminar flow and API filling, single-use bioreactor technology and more warehouse space for managing incoming material. The expansion work also included adding independently operated production units for upstream and downstream pDNA processing, linearization, mRNA production and a filling unit that helps maintain compliance, quality and flexibility for each project.
 
“The new addition to Heidelberg is a remarkable achievement for this site. We have integrated the latest single-use technology to support our unique plasmid DNA and messenger RNA offering,” said Dieter Kramer, Site General Manager, AGC Biologics Heidelberg. “This expansion complements our comprehensive capabilities and allows us to offer scalability for manufacturing and serve more developers in need of these materials worldwide.”